Effect of Missed Doses on the Therapeutic Effect of Methotrexate for Rheumatoid Arthritis: A Pharmacokinetic Modeling Study

References

• Maclean R, Pfister M, Zhou Z, Roy A, Tuomari VA, Heifets M. Quantifying the impact of nonadherence patterns on exposure to oral immunosuppressants. Ther Clin Risk Manag. 2011;2011(7):149–156. doi:10.2147/TCRM.S16870
   Web of Science ®Google Scholar
• Morrison A, Stauffer ME, Kaufman AS. Defining medication adherence in individual patients. Patient Prefer Adherence. 2015;9:893–897. doi:10.2147/PPA.S86249
   PubMed Web of Science ®Google Scholar
• Stauffer ME, Hutson P, Kaufman AS, Morrison A. The adherence rate threshold is drug specific. Drugs R D. 2017;17(4):645–653. doi:10.1007/s40268-017-0216-6
   Web of Science ®Google Scholar
• Kaufman AS, Morrison A. Patterns of non-adherence to oral antiretroviral medication: frequencies of consecutively missed doses. Patient Prefer Adherence. 2019;13:389–394. doi:10.2147/PPA.S192153
   Web of Science ®Google Scholar
• Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65(3):168–173.
   PubMedGoogle Scholar
• Inoue K, Yuasa H. Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy. Drug Metab Pharmacokinet. 2014;29(1):12–19. doi:10.2133/dmpk.DMPK-13-RV-119
   PubMed Web of Science ®Google Scholar
• Dalrymple JM, Stamp LK, O’Donnell JL, Chapman PT, Zhang M, Barclay ML. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2008;58(11):3299–3308. doi:10.1002/art.24034
   PubMed Web of Science ®Google Scholar
• de Rotte MC, den Boer E, de Jong PH, et al. Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74(2):408–414. doi:10.1136/annrheumdis-2013-203725
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank. Rheumatology. 2011;50(1):16–24. doi:10.1093/rheumatology/keq155
   Web of Science ®Google Scholar
• Michaud K, Vrijens B, Tousset E, et al. Real-world adherence to oral methotrexate measured electronically in patients with established rheumatoid arthritis. ACR Open Rheumatol. 2019;1(9):560–570. doi:10.1002/acr2.11079
   PubMedGoogle Scholar
• den Boer E, de Rotte MC, Pluijm SM, Heil SG, Hazes JM, de Jonge R. Determinants of erythrocyte methotrexate polyglutamate levels in rheumatoid arthritis. J Rheumatol. 2014;41(11):2167–2178. doi:10.3899/jrheum.131290
   PubMed Web of Science ®Google Scholar
• Angelis-Stoforidis P, Vajda FJ, Christophidis N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheumatol. 1999;17(3):313–320.
   PubMed Web of Science ®Google Scholar
• Dervieux T, Furst D, Lein DO, et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 2004;50(9):2766–2774. doi:10.1002/art.20460
   PubMed Web of Science ®Google Scholar
• Murosaki T, Nagatani K, Sato T, et al. Prediction of the therapeutic response to methotrexate at 24 weeks by methotrexate-polyglutamates concentration in erythrocytes at 8 weeks in patients with rheumatoid arthritis. Mod Rheumatol. 2017;27(3):411–416. doi:10.1080/14397595.2016.1208137
   PubMed Web of Science ®Google Scholar
• Takahashi C, Kaneko Y, Okano Y, et al. Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study. RMD Open. 2017;3(1):e000363. doi:10.1136/rmdopen-2016-000363
   PubMed Web of Science ®Google Scholar
• Stamp LK, O’Donnell JL, Chapman PT, et al. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis Rheum. 2010;62(2):359–368. doi:10.1002/art.27201
   PubMed Web of Science ®Google Scholar
• Pan S, Stamp LK, Duffull SB, et al. Assessment of the relationship between methotrexate polyglutamates in red blood cells and clinical response in patients commencing methotrexate for rheumatoid arthritis. Clin Pharmacokinet. 2014;53(12):1161–1170. doi:10.1007/s40262-014-0179-5
   Web of Science ®Google Scholar
• Dervieux T, Furst D, Lein DO, et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentre cross sectional observational study. Ann Rheum Dis. 2005;64(8):1180–1185. doi:10.1136/ard.2004.033399
   PubMed Web of Science ®Google Scholar
• Hornung N, Ellingsen T, Attermann J, Stengaard-Pedersen K, Poulsen JH. Patients with rheumatoid arthritis treated with methotrexate (MTX): concentrations of steady-state erythrocyte MTX correlate to plasma concentrations and clinical efficacy. J Rheumatol. 2008;35(9):1709–1715.
   PubMed Web of Science ®Google Scholar
• Hobl EL, Jilma B, Erlacher L, et al. A short-chain methotrexate polyglutamate as outcome parameter in rheumatoid arthritis patients receiving methotrexate. Clin Exp Rheumatol. 2012;30(2):156–163.
   Web of Science ®Google Scholar
• Calasan MB, den Boer E, de Rotte MC, et al. Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthritis patients. Ann Rheum Dis. 2015;74(2):402–407. doi:10.1136/annrheumdis-2013-203723
   PubMed Web of Science ®Google Scholar
• Lucas CJ, Dimmitt SB, Martin JH. Optimising low-dose methotrexate for rheumatoid arthritis-a review. Br J Clin Pharmacol. 2019;85(10):2228–2234. doi:10.1111/bcp.14057
   PubMed Web of Science ®Google Scholar
• Mohamed HJ, Sorich MJ, Kowalski SM, et al. The role and utility of measuring red blood cell methotrexate polyglutamate concentrations in inflammatory arthropathies–a systematic review. Eur J Clin Pharmacol. 2015;71(4):411–423. doi:10.1007/s00228-015-1819-x
   Web of Science ®Google Scholar
• Hua C, Barnetche T, Combe B, Morel J. Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res. 2014;66(7):1016–1026. doi:10.1002/acr.22246
   PubMed Web of Science ®Google Scholar
• Park JK, Lee YJ, Shin K, et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2018;77(6):898–904.
   PubMed Web of Science ®Google Scholar